B-Cell Depletion by Anti-CD20 (Rituximab) in Renal Allograft Recipients Who Develop Early de Novo Anti-HLA Alloantibodies Will Result in Inhibition of Alloantibody Production and Attenuation of Chronic Humoral Rejection
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Rituximab (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 23 Mar 2015 Biomarkers information updated
- 30 Apr 2013 Planned end date changed from 1 Mar 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 12 Apr 2012 Actual patient number is 780 according to ClinicalTrials.gov.